$7.21
Xeris Biopharma Holdings
Performance
Dividends
1W
1M
YTD
1Y
3Y
21/36
Growth
Score
17/36
Dividend
Score
Valuation
PE Ratio
-35.27
PS Ratio
4.75
RSI
-
0
PEG Ratio
0
3
PRG Ratio
0.04
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
76.09%
1
Gross Margin
37.11%
1
Current Ratio
1.95
Return on Assets
-9.56%
Return on Equity
113.91%
Return on inv. Capital
-3.62%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 203.07M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -54.84M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 166.24M
2018
2019
2020
2021
2022
2023
2024
6
Events
XERS
Xeris Biopharma Holdings
in 257 days
before market open
Earnings per Share is expected with - and revenue with - .
XERS
Xeris Biopharma Holdings
in 194 days
before market open
Earnings per Share is expected with - and revenue with - .
XERS
Xeris Biopharma Holdings
in 84 days
before market open
Earnings per Share is expected with $0.01 +116.67% and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
21.06.2018
MaketCap
1.17B
Country
US
CEO
John P. Shannon
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Updated 13.08.2025